Recruiting

Observational Study

Sponsor:

Invivoscribe, Inc.

Code:

NCT06222164

Conditions

Hematologic Diseases

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Acquire residual human specimens and/or samples from patient samples which were sent for testing at LabPMM, LLC for Clinical Research

Conditions

Hematologic Diseases

Study ID

NCT06222164

Start date

Mar 30, 2024

Status verified date

May, 2025

Completion date

Jun 30, 2027

Anticipated

Primary completion date

Mar 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Specimen/sample, peripheral blood (PB), bone marrow (BM), genomic DNA (gDNA) and/or formalin-fixed paraffin-embedded tissue (FFPE) from patients whose specimens/samples have been sent to LabPMM for clinical testing
2. Donor Age ≥ 18 years

Exclusion Criteria:

1. Sample/specimen has been obtained from a third-party vendor with a Materials Transfer Agreement (MTA) on file with LabPMM
2. The specimens/samples have previously been enrolled in a clinical study

Study Design

Enrollment

2000 participants

Anticipated

Interventions and Outcome Measures

Arms

Residual Specimens

Residual specimen/sample collection study where peripheral blood (PB), bone marrow (BM), genomic (gDNA), and/or formalin-fixed paraffin-embedded tissue (FFPE) specimens/samples are obtained from patient samples sent to LabPMM, LLC for clinical testing.

Primary outcome measure

  • Enrollment [ Time Frame: 3 years ]

Central Contacts and Locations

Central contacts

Andrew Schut

+1 858.224.6600aschut@invivoscribe.com

Locations

LabPMM

Recruiting

San Diego, California, United States, 92121

Contacts

Andrew Schut

858-224-6600aschut@invivoscribe.com

Principal Investigator:

Jordan Thornes

More Information

Sponsor

Invivoscribe, Inc.

Last update posted

May 4, 2025

Last verified

May, 2025

Keywords

  • residual samples hematologic diseases

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Invivoscribe, Inc. on 2025-05-04.